Chemomab Therapeutics Reports Q2 2026 Results and Raises Going Concern Doubt

Filing content

The company reported its Q2 2026 financial results and disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows. Additional funding is required to support operations.